-
The new licensable XS Technology™ Portfolio includes licensing
options for both E. coli and P. pastoris (Pichia) expression systems and platform fermentation protocols
- Platform fermentation
protocols are tailored to each XS™ Host System to build the foundation of
high-yielding, robust and scalable processes for ease of future scale-up and
production
- Multiple XS™ host and promoter combinations provide hundreds of options
for optimal expression of most types of microbial products
Basel, Switzerland, 5 November 2013 - Based on the clinical and commercial
success of Lonza’s Mammalian GS Gene Expression System™ licensing program, Lonza
now offers their XS Microbial Expression Technologies™ to customers under a Research
Evaluation Agreement. The new XS™
research license allows customers to use Lonza’s microbial expression hosts and
vectors in their own development laboratories.
The offering includes licensing options for both E. coli and P. pastoris
(Pichia) host systems, along with detailed fed-batch fermentation protocols
designed to quickly create commercially-viable production strains and GMP
processes. XS™ Systems
have been shown to deliver high titers with expression levels in excess of 20 g/L.
For difficult-to-express proteins, expression levels of up to 1 g/L have been
achieved, where alternatives were only achieving a few milligrams per liter.
Our customers have
achieved great success with our current research licensing programs, said Karen
Fallen, Vice President Head of Licensing, Lonza Custom Development Services. “By
expanding Lonza’s research license offering to include our XS™ Microbial System,
customers will have the opportunity to select the optimal expression platform
for their product of interest. The
research evaluation agreement is designed to be a comprehensive package that
includes prepared protocols and access to Lonza’s industry expression experts allowing
customers to streamline their early stages of development.”
The licensable XS
Technology™ Platform consists of multiple hosts and promoter systems that have
been optimized for
soluble expression driving simpler recovery and downstream processing, which
saves development time and costs. Each kit contains the key components
necessary to identify the best production clone for your product. Under the new
research evaluation agreement, customers will have access to the following XS
Technologies™:
-
XS™ Sugar Inducible E.
coli System
- XS™ IPTG Inducible E.
coli System
- XS™ GAP Constitutive
Pichia System
- XS™ Methanol Inducible
Pichia System
- XS™ Glucose Regulated
Pichia System
Host kits include 7
different E.coli strains and 6 E.coli plasmids; 1 Pichia strain and 6 Pichia plasmids.
The extent of portfolio availability varies by country.
In addition, Lonza
customers will have numerous options for additional technical support
including: notification of system upgrades, visits to customer sites as part of
XS Technology™ Tours, and access to technical experts by phone or e-mail. Before filing an IND, an XS™ Commercial
License may be obtained to cover the clinical development and commercial stages
for the candidate drug or vaccine.
For more
information on Lonza’s XS Technology Platforms, please visit www.lonza.com/xs.
